Although the slideshow didn't give totals, or say what percentage of Sanofi's total workforce will be laid off, it did describe individual cuts in various geographies and divisions. The edited highlights might be retitled "Sanofi's PowerPoint of Doom": It shows who faces the ax, and how much more Viehbacher wants to cut before he's done.
The goal: Saving 2 billion a year in costs
It's all about money, of course. Patent expiries have created cheap competition that wiped â‚¬778 million from Sanofi's Q2 2011 revenues, reducing sales to â‚¬8.35 billion.
This slide shows how Viehbacher's ax-swinging is ahead of schedule. He intended to reach his â‚¬2 billion target in 2013, but Sanofi will be there by the end of this year.
3,000 jobs gone in R&D
Sanofi will spend less money on its own research and instead acquire and license development products from other companies. That means the company needs 3,000 fewer scientists and R&D support staff.
6,500 drug sales reps laid off
From 2008 through 2011, Sanofi will have laid off 6,500 pharma sales reps. About 3,800 of those will be in the U.S. and the rest in Europe.
46 percent of American salespersons gone
In 2008, Sanofi had more than 8,300 people selling its drugs. By the end of the year 46 percent of those workers will be gone, leaving just 4,500 employed by the company. It's a similar picture in Europe. In emerging markets, however, the company added 3,720 jobs.
By the time Viehbacher is done, according to numbers presented in the slideshow and the company's previous annual reports, Sanofi's total headcount (which was 100,000 in 2008 and 101,575 at the end of last year, should settle at around 94,220.
- Multaq Meltdown: Heart Flutter Drug Actually Causes Heart Failure, FDA Says
- The French Chefs at Sanofi See a Rat in Genzyme's Kitchen